Ligand Pharmaceuticals Incorporated (LGND) Drops 5.3% on January 04

Equities Staff |

Ligand Pharmaceuticals Incorporated (LGND) was one of the Russell 2000's biggest losers for Monday January 04 as the stock slid 5.3% to $102.68, a loss of $-5.745 per share. Starting at an opening price of $106.06 a share, the stock traded between $102.49 and $107.26 over the course of the trading day. Volume was 255,712 shares over 2,815 trades, against an average daily volume of 325,095 shares and a total float of 19.93 million.

The losses send Ligand Pharmaceuticals Incorporated down to a market cap of $2.05 billion. In the last year, Ligand Pharmaceuticals Incorporated has traded between $114.00 and $49.65, and its 50-day SMA is currently $101.75 and 200-day SMA is $93.69.

The stock has a P/E Ratio of 9.1.

Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals Incorporated is based out of La Jolla, CA and has some 19 employees. Its CEO is John L. Higgins.

For a complete fundamental analysis analysis of Ligand Pharmaceuticals Incorporated, check out’s Stock Valuation Analysis report for LGND. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

H-Source Holdings Ltd.

H-Source Holdings Inc. is a technology company operating within the healthcare industry through its subsidiary, H-Source, Inc. The Company has developed a transaction platform that provides a private, secure and…

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…